Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 8 art units • 10 examiners • 0 of 15 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Sapreme Technologies B V has 15 pending office actions in Biotechnology & Pharmaceuticals. The portfolio is distributed across 10 distinct examiners and 8 distinct art units, showing that its prosecution workload extends across multiple examination assignments rather than a single channel.
SKOKO III, JOHN JOSEPH is the busiest examiner, with 3 pending matters. That assignment is the largest identified examiner concentration, but it represents only part of the broader portfolio structure. Counsel should maintain a centralized docket while preserving matter-level analysis of claim scope, cited art, and response timing.
The combination of 15 pending actions and 10 examiners creates a coordination issue as well as a substantive prosecution issue. Art-unit-specific review can help identify recurring examination themes, while examiner-specific records can distinguish portfolio-wide concerns from issues limited to particular applications. The 8 art-unit assignments also support tracking whether similar claim strategies are being reviewed under materially different examination practices.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §103 only | 3 (20%) |
| §112 only | 1 (7%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 5 (33%) |
| Multi-statute (no §101) | 4 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 3 | 53.0% | +55.2% |
| HUYNH, PHUONG N | 2 | 65.8% | +53.6% |
| CREWS, JARET JAMES | 2 | 43.9% | +71.3% |
| ZARA, JANE J | 2 | 71.0% | +16.1% |
| SU-TOBON, QIWEN NMN | 1 | 66.7% | +66.7% |
| CHONG, KIMBERLY | 1 | 72.3% | +13.1% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| HIBSHMAN, SARAH GRACE | 1 | 38.2% | +40.7% |
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
| BAKSHI, PANCHAM | 1 | 76.7% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17312193 | SAPONIN CONJUGATED TO EPITOPE-BINDING PROTEINS | HUYNH, PHUONG N | 22d |
| 18012723 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | SKOKO III, JOHN JOSEPH | 69d |
| 18564885 | CYTOSOLIC DELIVERY OF GENOME EDITING TOOLS | SU-TOBON, QIWEN NMN | — |
| 18012760 | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND AN ANTIBODY-SAPONIN CONJUGATE | HUYNH, PHUONG N | — |
| 17312104 | Saponin Conjugates | BAKSHI, PANCHAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17415759 | DRUG CONJUGATE | ZARA, JANE J | 30d overdue |
| 18044945 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | CHONG, KIMBERLY | 9d overdue |
| 18012694 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | CREWS, JARET JAMES | 1d overdue |
| 17629796 | Saponin derivatives with improved therapeutic window | CREWS, JARET JAMES | 7d |
| 18012710 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | PUTTLITZ, KARL J | 14d |
| 17312193 | SAPONIN CONJUGATED TO EPITOPE-BINDING PROTEINS | HUYNH, PHUONG N | 22d |
| 18012741 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | SKOKO III, JOHN JOSEPH | 26d |
| 17629598 | BIOACTIVE SAPONIN LINKED TO A FUNCTIONAL MOIETY | LEE, HOI YAN NMN | 34d |
| Art Unit | Apps |
|---|---|
| 1643 | 3 |
| 1636 | 2 |
| 1641 | 2 |
| 1691 | 2 |
| 1693 | 2 |
| 1637 | 2 |
| 1646 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18564885 | CYTOSOLIC DELIVERY OF GENOME EDITING TOOLS | SU-TOBON, QIWEN NMN | 1636 | §101§102§103§112DP | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18044945 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | CHONG, KIMBERLY | 1636 | §103§112DP | Final Rejection | 9d overdue | Pending | Mar 10, 2023 |
| 18012710 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | PUTTLITZ, KARL J | 1646 | DP | Final Rejection | 14d | Pending | Dec 23, 2022 |
| 18012741 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | SKOKO III, JOHN JOSEPH | 1643 | §103Other | Final Rejection | 26d | Pending | Dec 23, 2022 |
| 18012760 | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND AN ANTIBODY-SAPONIN CONJUGATE | HUYNH, PHUONG N | 1641 | §103§112Other | Final Rejection | — | Pending | Dec 23, 2022 |
| 18012694 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 1d overdue | Pending | Dec 23, 2022 |
| 18012791 | HYDRAZONE-BASED SAPONIN DERIVATIVES | HIBSHMAN, SARAH GRACE | 1693 | §103§112DP | Non-Final OA | — | Pending | Dec 23, 2022 |
| 18012769 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | ZARA, JANE J | 1637 | §112DP | Non-Final OA | — | Pending | Dec 23, 2022 |
| 18012754 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | SKOKO III, JOHN JOSEPH | 1643 | §103§112DP | Non-Final OA | — | Pending | Dec 23, 2022 |
| 18012723 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | SKOKO III, JOHN JOSEPH | 1643 | §103§112Other | Final Rejection | 69d | Pending | Dec 23, 2022 |
| 17629796 | Saponin derivatives with improved therapeutic window | CREWS, JARET JAMES | 1691 | §112Other | Final Rejection | 7d | Pending | Jan 25, 2022 |
| 17629598 | BIOACTIVE SAPONIN LINKED TO A FUNCTIONAL MOIETY | LEE, HOI YAN NMN | 1693 | §103Other | Final Rejection | 34d | Pending | Jan 24, 2022 |
| 17415759 | DRUG CONJUGATE | ZARA, JANE J | 1637 | §103§112DP | Final Rejection | 30d overdue | Pending | Jun 18, 2021 |
| 17312104 | Saponin Conjugates | BAKSHI, PANCHAM | 1623 | §102§112 | Non-Final OA | — | Pending | Jun 09, 2021 |
| 17312193 | SAPONIN CONJUGATED TO EPITOPE-BINDING PROTEINS | HUYNH, PHUONG N | 1641 | §103§112Other | Final Rejection | 22d | Pending | Jun 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSapreme Technologies B V has 15 pending office actions as of October 2026, spread across 8 art units and 10 examiners.
John Joseph Skoko III has the most, with 3 of Sapreme Technologies B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
